Foundation / Corporation
Grants and awards to USA, Canada, and International researchers with an advanced degree (i.e., MD, PhD, MS, or PharmD), for scientific research projects that could result in new treatments for people with epilepsy. To start the application process, applicants must submit a letter of intent. Funding is intended to accelerate therapies onto the market in a timeframe that will make a difference.
ETP provides new therapy commercialization grants (NTCG) to support later-stage development projects past proof of concept stages. For projects that are beyond the resources of the Epilepsy Foundation, applicants can also apply for an Epilepsy Innovation Seal of Excellence award (SEAL). The SEAL is not a grant program but an official housekeeping seal of approval that a team can use to generate further venture capital interest. The SEAL awards undergo the same application and review process as the NTCG.
Areas of interest for the Foundation include:
- Novel approaches to treatment.
- Platform technology to advance screening techniques that can be utilized by multiple laboratories, including utility of techniques for early proof-of-concept trials.
- Adaptation of treatment in development for another therapeutic area to assess utility for epilepsy (while maintaining patent protection).
These grants support the development of more effective therapies by serving as a catalyst for moving innovative therapies from the laboratory to the patient. Note that preference will be given to proposals that already have a commercial partner engaged to assist with development and to proposals that have committed or matched funding from the sponsoring institution, commercial partner or other third-party source. For the New Therapy Commercialization Grants, applicants must demonstrate background work beyond the proof of concept / basic science discovery stage.
The Foundation supports projects spanning diagnostics and devices to small molecules and biologics. For programs that seek to develop diagnostics and/or devices, projects must be in later stage feasibility testing or in the proof of value stage (i.e. there should be a minimal viable product (MVP) prototype with a product IFU (instructions for use) to be competitive. For programs that seek to develop potential drugs through small molecules and biologics, there must be at least one lead compound identified, which may be at the pre-IND (Investigational New Drug application) to be competitive for a New Therapy Commercialization Grant. Investigators of drugs are strongly advised to have their compounds screened, as appropriate, by the NINDS ETSP Program prior to applying.
Priorities Will Be Given To:
- Research programs that might not otherwise be funded through traditional sources.
- Projects that encourage collaboration among scientists and industry.
- Projects with full intellectual property (IP) rights (composition of matter) are preferred over method of use IP.
GrantWatch ID#: 180289
New Therapy Commercialization grants are up to $350,000 for a maximum of 2 years.
The Epilepsy Innovation Seal of Excellence Award comes with no award dollars but an official housekeeping seal of approval that can be used to generate further venture capital funds.
New Therapy Commercialization funding is for a period of one to two years.
Investigators must hold a relevant advanced degree (MD, PhD, MS, PharmD), and have completed all research training appropriate to the project proposed. Investigators may come from public and/or private sectors. The Foundation also considers international applications.
Funds may NOT be allocated for travel, administrative purposes, or equipment.
The Epilepsy Foundation will not award funds to duplicate any work that is being supported by other funding agencies.
Letters of Intent due: January 28, 2019
Full Grant Proposal due: April 1, 2019
Applications are submitted electronically via the proposalCentral system.
LOIs will be reviewed within approximately two weeks after the LOI submission deadline, at which time Principal Investigators / Contact People will be notified if a full proposal is or is not invited for submission for a full review.
Note that 1:1 matching grants are encouraged, and preference will be given to proposals that already have a commercial partner engaged to assist with development and to proposals that have committed or matched funding from the sponsoring institution, commercial partner or other third party source.
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
For help with electronic application process, please contact the help desk for proposalCENTRAL: email@example.com or 1-800-875-2562.
For questions, contact firstname.lastname@example.org or email@example.com.
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA) Guam (USA) Puerto Rico (USA) Virgin Islands (USA) Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
International country outside of the USA, Israel and Canada.